OSTX:NYE-OS Therapies Incorporated (USD)

COMMON STOCK | Biotechnology |

Last Closing

USD 2.52

Change

-0.11 (-4.18)%

Market Cap

USD 0.07B

Volume

0.06M

Analyst Target

N/A
Analyst Rating

N/A

ducovest Verdict

Verdict

About

OS Therapies Incorporated, a clinical stage biopharmaceutical company, focuses on the identification, development, and commercialization of treatments for osteosarcoma and other solid tumors in the United States. Its pipeline includes OST-HER2, an off-the-shelf immunotherapy for osteosarcoma patients; and OST-tunable drug conjugate (OST-tADC), an antibody-drug conjugate technology, with a plug-and-play platform that features tunable pH sensitive silicone linkers. OS Therapies Incorporated was incorporated in 2018 and is based in Rockville, Maryland.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-11-13 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap
BHVN Biohaven Pharmaceutical Holdin..

-1.32 (-2.62%)

USD 5.08B
RCUS Arcus Biosciences Inc

-0.34 (-2.03%)

USD 1.44B
NUVB Nuvation Bio Inc

+0.02 (+0.68%)

USD 0.74B
DNA Ginkgo Bioworks Holdings

+0.21 (+2.50%)

USD 0.47B
ANRO Alto Neuroscience, Inc.

+0.03 (+0.67%)

USD 0.37B
ADCT ADC Therapeutics SA

-0.11 (-3.75%)

USD 0.28B
CYBN Cybin Inc

-1.20 (-10.26%)

USD 0.21B
ANVS Annovis Bio Inc

-0.13 (-1.72%)

USD 0.10B
ARMP Armata Pharmaceuticals Inc

-0.03 (-1.09%)

USD 0.10B
PLX Protalix Biotherapeutics Inc

-0.08 (-6.06%)

USD 0.09B

ETFs Containing OSTX

N/A

Market Performance

  Market Performance vs. Industry/Classification (Biotechnology) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Trailing 12 Months  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) N/A N/A N/A N/A N/A
Risk Adjusted Return N/A N/A N/A N/A N/A
Market Capitalization 0.07B 63% D 24% F

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:

There is nothing we particularly like

What to not like:
Negative cashflow

The company had negative total cash flow in the most recent four quarters.